Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Hotta, K.
Kiura, K.
Takigawa, N.
Tabata, M.
Fujiwara, Y.
Tanimoto, M.
机构：
[1] Okayama Univ, Grad Sch Med, Dept Hematol Oncol & Resp Med, Okayama, Japan
[2] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[3] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan
[4] Okayama Univ, Tsuyama Cent Hosp, Okayama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7624
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7624
引用
收藏
页数：1
相关论文
共 50 条
  • [11] THE OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) OF HYPERPROGRESSIVE DISEASE (HDP) IN LUNG CANCER PATIENTS
    Oh, Youjin
    Djunadi, Trie Arni
    Chung, Liam Il-Young
    Lee, Soowon
    Hong, Timothy
    Shah, Zunairah
    Park, Joo Hee
    Yoon, Sung Mi
    Duan, Richard
    Chae, Young Kwang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1468 - A1469
  • [12] LONG-TERM EXTRAPOLATION OF OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) FOR THE LUNAR TRIAL IN METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING PROGRESSION ON PLATINUM-BASED THERAPY
    Wang, B.
    Wu, E.
    Nino, de Rivera Guzman J.
    VALUE IN HEALTH, 2024, 27 (12)
  • [13] Meta-analysis of progression-free survival as a predictor of overall survival in locally advanced or metastatic non-small cell lung cancer trials.
    Turner, Evadne Jane
    McCloud, Philip
    Germanos, Peter
    Dehle, Francis
    Norris, Sarah
    Tan, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [14] Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer
    Hotta, Katsuyuki
    Suzuki, Etsuji
    Di Maio, Massimo
    Chiodini, Paolo
    Fujiwara, Yoshiro
    Takigawa, Nagio
    Ichihara, Eiki
    Reck, Martin
    Manegold, Christian
    Pilz, Lothar
    Hisamoto-Sato, Akiko
    Tabata, Masahiro
    Tanimoto, Mitsune
    Shepherd, Frances A.
    Kiura, Katsuyuki
    LUNG CANCER, 2013, 79 (01) : 20 - 26
  • [15] Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data
    Ton, Thanh G. N.
    Pal, Navdeep
    Trinh, Huong
    Mahrus, Sami
    Bretscher, Michael T.
    Machado, Robson J. M.
    Sadetsky, Natalia
    Chaudhary, Nayan
    Lu, Michael W.
    Riely, Gregory J.
    CLINICAL CANCER RESEARCH, 2022, 28 (13) : 2844 - 2853
  • [16] Design of clinical studies: Adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC)
    Sohrimpf, Daniel
    Manegold, Christian
    Pilz, Lothar R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (01) : 84 - 86
  • [17] Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John Frederick
    Goss, Glenwood D.
    Fung-Kee-Fung, Michael
    Jonker, Derek J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [18] Superior overall survival (OS), progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula: myCare-022-05.
    Velcheti, Vamsidhar
    Castro, Michael
    Watson, Drew
    Kapoor, Shweta
    Tyagi, Anuj
    Sauban, Mohammed
    Alam, Aftab
    Roy, Kunal Ghosh
    Rajagopalan, Swaminathan
    Kulkarni, Shruthi
    Mundkur, Nirjhar
    Christie, Jim
    Suseela, Rakhi Purushothaman
    Ghosh, Adity
    Basu, Kabya
    Sahu, Diwyanshu
    Ullal, Yashaswini
    Nair, Prashant
    Ahluwalia, Manmeet Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [19] Increasing progression-free survival in non-small cell lung cancer
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2009, 70 (09) : 498 - 498
  • [20] DYNAMIC PREDICTION OF PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN NON-SMALL CELL LUNG CANCER (NSCLC) USING TUMOR SIZE: A LONGITUDINAL JOINT MODELING APPROACH.
    Al-Huniti, N.
    Onishchenko, D.
    Xu, H.
    Zhou, D.
    Masson, E.
    Helmlinger, G.
    Tomkinson, H.
    Abdallah, K.
    Dunyak, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S55 - S55
12345